Ian W. Flinn, MD, PhD | Authors


Polatuzumab Shows Improved Survival and Complete Responses in R/R DLBCL

July 06, 2022

Ian W. Flinn, MD, PhD, discusses the study design and results of the phase 2 trial of the antibody-drug conjugate polatuzumab vedotin-piiq plus bendamustine and rituximab for patients with relapsed/refractory diffuse large B-cell lymphoma.

Cerdulatinib in Relapsed/Refractory B-Cell Malignancies

June 03, 2015

Ian W. Flinn, MD, PhD, director, Blood Cancer Research Program, principal investigator, Sarah Cannon Research Institute, discusses a phase I story which examined cerdulatinib in patients with relapsed/refractory B-cell malignancies.